Karen Stevens

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. doi request reprint Permanent improvement in deficient sensory inhibition in DBA/2 mice with increased perinatal choline
    Karen E Stevens
    Medical Research, Veterans Affairs Medical Center, 1055 Clermont Avenue, Denver, CO 80220, USA
    Psychopharmacology (Berl) 198:413-20. 2008
  2. ncbi request reprint Input dysfunction, schizotypy, and genetic models of schizophrenia
    Robert Freedman
    Department of Psychiatry and Pharmacology, University of Colorado Health Sciences Center, Campus Box C 268 71, 4200 E Ninth Avenue, Denver, CO 80262, USA
    Schizophr Res 54:25-32. 2002
  3. pmc Initial phase 2 trial of a nicotinic agonist in schizophrenia
    Robert Freedman
    Department of Psychiatry, Denver VA Medical Center and University of Colorado, Denver, CO 80262, USA
    Am J Psychiatry 165:1040-7. 2008
  4. pmc An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients
    Daniel J Abrams
    Department of Psychiatry, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, United States
    Schizophr Res 100:86-96. 2008
  5. pmc Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men
    Ann Olincy
    Department of Psychiatry, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA
    Biochem Pharmacol 74:1192-201. 2007
  6. ncbi request reprint Evidence for a role of nicotinic acetylcholine receptors in schizophrenia
    Catherine E Adams
    Department of Psychiatry, Veterans Affairs Medical Center, Denver, CO 80220, USA
    Front Biosci 12:4755-72. 2007
  7. pmc Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators
    Herman J Ng
    Department of Pharmacology, School of Medicine, University of California, Irvine, CA 92697, USA
    Proc Natl Acad Sci U S A 104:8059-64. 2007
  8. ncbi request reprint Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia
    Ann Olincy
    Department of Veterans Affairs Schizophrenia Research Center, Denver, Colorado, USA
    Arch Gen Psychiatry 63:630-8. 2006
  9. ncbi request reprint Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors
    Kenji Hashimoto
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1 8 1 Inohana, Chiba, Chiba 260 8670, Japan
    Psychopharmacology (Berl) 183:13-9. 2005
  10. pmc Early biomarkers of psychosis
    Robert Freedman
    Department of Psychiatry C 268 71, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Dialogues Clin Neurosci 7:17-29. 2005

Research Grants

  1. Gestational Choline Levels and Sensory Inhibition
    Karen Stevens; Fiscal Year: 2007
  2. GENETIC LINKAGE OF AUDITORY GATING
    Karen Stevens; Fiscal Year: 1999
  3. GENETIC LINKAGE OF AUDITORY GATING
    Karen Stevens; Fiscal Year: 2000
  4. GENETIC LINKAGE OF AUDITORY GATING
    Karen Stevens; Fiscal Year: 2001
  5. Gestational Choline Levels and Sensory Inhibition
    Karen Stevens; Fiscal Year: 2006

Collaborators

Detail Information

Publications17

  1. doi request reprint Permanent improvement in deficient sensory inhibition in DBA/2 mice with increased perinatal choline
    Karen E Stevens
    Medical Research, Veterans Affairs Medical Center, 1055 Clermont Avenue, Denver, CO 80220, USA
    Psychopharmacology (Berl) 198:413-20. 2008
    ..Increasing maternal dietary choline, a selective alpha7 agonist, during gestation has been shown to produce long-term changes in adult offspring behavior (i.e., improved learning and memory in rats)...
  2. ncbi request reprint Input dysfunction, schizotypy, and genetic models of schizophrenia
    Robert Freedman
    Department of Psychiatry and Pharmacology, University of Colorado Health Sciences Center, Campus Box C 268 71, 4200 E Ninth Avenue, Denver, CO 80262, USA
    Schizophr Res 54:25-32. 2002
    ..Thus, as predicted by Venables, the substrates of schizotypy and schizophrenia may arise from variants in normal brain function...
  3. pmc Initial phase 2 trial of a nicotinic agonist in schizophrenia
    Robert Freedman
    Department of Psychiatry, Denver VA Medical Center and University of Colorado, Denver, CO 80262, USA
    Am J Psychiatry 165:1040-7. 2008
    ..The agent 3-(2,4-dimethoxybenzylidene) anabaseine (DMXB-A) is a partial alpha(7)-nicotinic agonist and can be taken orally. A phase 1 trial showed evidence for cognitive enhancement in schizophrenia...
  4. pmc An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients
    Daniel J Abrams
    Department of Psychiatry, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, United States
    Schizophr Res 100:86-96. 2008
    ....
  5. pmc Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men
    Ann Olincy
    Department of Psychiatry, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA
    Biochem Pharmacol 74:1192-201. 2007
    ..These data suggest that therapeutic agents selected for alpha7 nicotinic activity may have utility in treating certain symptoms of schizophrenia...
  6. ncbi request reprint Evidence for a role of nicotinic acetylcholine receptors in schizophrenia
    Catherine E Adams
    Department of Psychiatry, Veterans Affairs Medical Center, Denver, CO 80220, USA
    Front Biosci 12:4755-72. 2007
    ..The initial results from clinical trials of these new drugs appear promising, potentially opening new avenues of treatment for this devastating disease...
  7. pmc Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators
    Herman J Ng
    Department of Pharmacology, School of Medicine, University of California, Irvine, CA 92697, USA
    Proc Natl Acad Sci U S A 104:8059-64. 2007
    ..Compound 6 represents a chemotype for allosteric activation of alpha7 nAChRs, with therapeutic potential in CNS diseases with cognitive dysfunction...
  8. ncbi request reprint Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia
    Ann Olincy
    Department of Veterans Affairs Schizophrenia Research Center, Denver, Colorado, USA
    Arch Gen Psychiatry 63:630-8. 2006
    ....
  9. ncbi request reprint Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors
    Kenji Hashimoto
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1 8 1 Inohana, Chiba, Chiba 260 8670, Japan
    Psychopharmacology (Berl) 183:13-9. 2005
    ..Similar to schizophrenic patients, DBA/2 mice spontaneously exhibit a deficit in inhibitory processing of the P20-N40 auditory evoked potential, which is thought to be a rodent analog of the human P50 auditory evoked potential...
  10. pmc Early biomarkers of psychosis
    Robert Freedman
    Department of Psychiatry C 268 71, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Dialogues Clin Neurosci 7:17-29. 2005
    ..Examples are given from work on the role of the alpha(T)nicotinic receptor and its gene CHRNA7 on chromosome 15 in the neurobiology and genetic transmission of schizophrenia...
  11. ncbi request reprint Tropisetron improves deficits in auditory P50 suppression in schizophrenia
    Kaori Koike
    Department of Psychiatry, Chiba University Graduate School of Medicine, Japan
    Schizophr Res 76:67-72. 2005
    ..These data are consistent with biological activity at a pathophysiological mechanism in schizophrenia and support further trials of this drug as a possible therapeutic for neurocognitive deficits in schizophrenia...
  12. ncbi request reprint Lithium alters measures of auditory gating in two strains of mice
    Heidi C O'Neill
    Department of Psychiatry, University of Colorado Health Sciences Center, C268 71, 4200 East 9th Avenue, Denver, CO 80262, USA
    Biol Psychiatry 54:847-53. 2003
    ..Lithium has been used to treat psychosis acutely in both bipolar disorder and schizophrenia. An animal model was used to assess the effects of lithium treatment on normal and deficient auditory gating...
  13. ncbi request reprint DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats
    Heidi C O'Neill
    Department of Psychiatry C268 71, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA
    Psychopharmacology (Berl) 169:332-9. 2003
    ..3-(2,4)-Dimethoxybenzylidine anabaseine (DMXB; also known as GTS-21) is such an agonist and has shown efficacy in mice both orally and intraperitoneally...
  14. ncbi request reprint The genetics of sensory gating deficits in schizophrenia
    Robert Freedman
    Departments of Psychiatry and Pharmacology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, C 268 71, Denver, CO 80262, USA
    Curr Psychiatry Rep 5:155-61. 2003
    ..Polymorphisms in the core promoter of the gene are associated with schizophrenia and also with diminished inhibition of the P50 response. These genetic data may identify a new pathophysiologic target for drug discovery...
  15. ncbi request reprint Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism
    Johanna K Simosky
    Department of Pharmacology, University of Colorado Health Sciences Center, Campus Box C268 71, 4200 East 9th Avenue, Denver, CO 80262, USA
    Psychopharmacology (Berl) 165:386-96. 2003
    ..The atypical antipsychotic clozapine also normalizes this deficit in schizophrenia patients, but by an unknown mechanism...
  16. pmc Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice
    Kristin M Wildeboer
    Department of Psychiatry, University of Colorado Denver, Aurora, CO 80045, USA
    Brain Res 1224:29-36. 2008
    ..Thus, the present study implicates the involvement of more than one subtype of nAChR in the auditory gating of DBA/2 mice, specifically the alpha4beta2 nAChR, and its role in the response amplitude to the first stimulus...
  17. pmc Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats
    Neal R Swerdlow
    Department of Psychiatry, UCSD School of Medicine, La Jolla, CA 92093 0804, USA
    Neuropsychopharmacology 31:506-15. 2006
    ..Despite similarities in drug sensitivity, these results suggest that distinct neurobiological mechanisms underlie drug-induced deficits in PPI and N40 gating...

Research Grants6

  1. Gestational Choline Levels and Sensory Inhibition
    Karen Stevens; Fiscal Year: 2007
    ..The data from these studies may potentially impact guide lines for human prenatal nutrition in at-risk pregnancies for schizophrenia. ..
  2. GENETIC LINKAGE OF AUDITORY GATING
    Karen Stevens; Fiscal Year: 1999
    ..Such information could be important in understanding of the etiology of the disorder and in determining future therapeutic interventions. ..
  3. GENETIC LINKAGE OF AUDITORY GATING
    Karen Stevens; Fiscal Year: 2000
    ..Such information could be important in understanding of the etiology of the disorder and in determining future therapeutic interventions. ..
  4. GENETIC LINKAGE OF AUDITORY GATING
    Karen Stevens; Fiscal Year: 2001
    ..Such information could be important in understanding of the etiology of the disorder and in determining future therapeutic interventions. ..
  5. Gestational Choline Levels and Sensory Inhibition
    Karen Stevens; Fiscal Year: 2006
    ..The data from these studies may potentially impact guide lines for human prenatal nutrition in at-risk pregnancies for schizophrenia. ..